Patents by Inventor Patrick J. Salvo
Patrick J. Salvo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260159501Abstract: Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.Type: ApplicationFiled: October 1, 2025Publication date: June 11, 2026Inventors: Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, David L. Kukla, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
-
Patent number: 12459922Abstract: Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.Type: GrantFiled: January 26, 2023Date of Patent: November 4, 2025Assignee: Gilead Sciences, Inc.Inventors: Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, David L Kukla, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
-
Publication number: 20250163030Abstract: Provided herein is a compound of Formula (I) wherein the various substituents are described herein.Type: ApplicationFiled: October 24, 2024Publication date: May 22, 2025Inventors: Gayatri Balan, Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, Jeffrey E. Kropf, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
-
Publication number: 20250100998Abstract: Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.Type: ApplicationFiled: July 26, 2024Publication date: March 27, 2025Inventors: Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, David L. Kukla, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
-
Patent number: 12258346Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: GrantFiled: December 18, 2023Date of Patent: March 25, 2025Assignee: Gilead Sciences, Inc.Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A Codelli, John H. Conway, Jennifer L Cosman Ellis, Rao V. Kalla, Zachary A Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Publication number: 20250066328Abstract: Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present disclosure, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.Type: ApplicationFiled: July 25, 2024Publication date: February 27, 2025Inventors: Jonah J. Chang, Jayaraman Chandrasekhar, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, David L. Kukla, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
-
Publication number: 20240287061Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: ApplicationFiled: December 18, 2023Publication date: August 29, 2024Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman Ellis, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Patent number: 11925631Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: GrantFiled: May 27, 2021Date of Patent: March 12, 2024Assignee: Gilead Sciences, Inc.Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Patent number: 11897878Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: GrantFiled: November 9, 2021Date of Patent: February 13, 2024Assignee: Gilead Sciences, Inc.Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C Yeung, Jeff Zablocki
-
Publication number: 20230365529Abstract: Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.Type: ApplicationFiled: January 26, 2023Publication date: November 16, 2023Inventors: Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, David L. Kukla, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
-
Publication number: 20230183216Abstract: Provided herein is a compound of Formula (I) wherein the various substituents are described herein.Type: ApplicationFiled: October 27, 2022Publication date: June 15, 2023Inventors: Gayatri Balan, Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, Jeffrey E. Kropf, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
-
Publication number: 20230013585Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: ApplicationFiled: May 27, 2021Publication date: January 19, 2023Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Publication number: 20220213091Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: ApplicationFiled: November 9, 2021Publication date: July 7, 2022Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Patent number: 11203591Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: GrantFiled: October 30, 2019Date of Patent: December 21, 2021Assignee: Gilead Sciences, Inc.Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Patent number: 11071730Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: GrantFiled: October 30, 2019Date of Patent: July 27, 2021Assignee: Gilead Sciences, Inc.Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Publication number: 20210115037Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: ApplicationFiled: October 30, 2019Publication date: April 22, 2021Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Publication number: 20200171020Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: ApplicationFiled: October 30, 2019Publication date: June 4, 2020Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
